Securities code: 002107 securities abbreviation: Shandong Wohua Pharmaceutical Co.Ltd(002107) Announcement No.: 2022-016 Shandong Wohua Pharmaceutical Co.Ltd(002107)
Announcement on the proposed independent director
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
On January 19, 2022, Shandong Wohua Pharmaceutical Co.Ltd(002107) (hereinafter referred to as the company) held the 17th meeting of the sixth board of directors, deliberated and adopted the proposal on nominating candidates for directors of the seventh board of directors of the company. The board of directors of the company nominated Mr. Li Junde, Ms. Gao Mingqin and Mr. Yu Junli as candidates for independent directors of the seventh board of directors of the company, with a term of office of three years, calculated from the date of adoption of the resolution of the general meeting of shareholders.
Mr. LV Wei and Ms. Peng Juan, the former independent directors of the company, cannot continue to serve as independent directors of the company in accordance with relevant regulations due to the expiration of their six-year re-election. The board of directors of the company expressed heartfelt thanks to the above two independent directors for their contributions to the development of the company during their tenure.
As of the date of this announcement, Mr. Li Junde and Ms. Gao Mingqin, the independent directors to be appointed by the company, have obtained the qualification certificate of independent directors in accordance with the guidelines for the training of senior managers of listed companies issued by the CSRC; Mr. Yu Junli has not obtained the independent director qualification certificate yet, but has made a written commitment to participate in the latest independent director training and obtain the independent director qualification certificate recognized by Shenzhen Stock Exchange. Three independent directors to be appointed concurrently as independent directors of other listed companies shall not exceed 5.
The qualification and independence of independent director candidates shall be reviewed by Shenzhen Stock Exchange and submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
See the announcement on resolutions of the 17th meeting of the 6th board of directors issued by the company on the same day for the resume of independent director candidates.
January 20, 2002
